Back to mobile site

UBS Reiterates Neutral Rating on Regeneron Pharma (REGN)

June 3, 2025 8:18 AM EDT Send to a Friend
UBS analyst Trung Huynh reiterated a Neutral rating and $633.00 price target on Regeneron Pharma (NASDAQ: REGN).The analyst comments "Bottom-line ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login